Shares of [finviz_code ticker=CBIO item=2 value=”Catalyst Biosciences, Inc.”] (NASDAQ:[finviz_code ticker=CBIO item=1 value=”CBIO”]) are currently up by more than [finviz_code ticker=CBIO item=60 value=”-25.83%”] from the open today and are trading at $[finviz_code ticker=CBIO item=65 value=”7.90″]. More than [finviz_code ticker=CBIO item=67 value=”525,155″] shares have exchanged hands compared to an average trading volume of [finviz_code ticker=CBIO item=63 value=”624.60K”]. At the current pps, the market cap stands at $[finviz_code ticker=CBIO item=6 value=”121.79M”]. The stock prices of [finviz_code ticker=CBIO item=2 value=”Catalyst Biosciences, Inc.”] (NASDAQ:[finviz_code ticker=CBIO item=1 value=”CBIO”]) are currently trading at [finviz_code ticker=CBIO item=57 value=”-27.86%”] below its 52 week high and [finviz_code ticker=CBIO item=58 value=”1655.40%”] above its 52 week low.
[finviz_code ticker=CBIO item=2 value=”Catalyst Biosciences, Inc.”] (NASDAQ:[finviz_code ticker=CBIO item=1 value=”CBIO”]) has been in the news for all the right reasons. Recently, [finviz_code ticker=CBIO item=2 value=”Catalyst Biosciences, Inc.”] (NASDAQ:[finviz_code ticker=CBIO item=1 value=”CBIO”]) announced an update on its clinical development plans for its next-generation Factor VIIa and Factor IX candidates and reiterated its intention to commence two clinical trials in individuals with hemophilia B in 2017.
The Company plans to initiate a subcutaneous (SQ) efficacy trial of marzeptacog alfa (activated), a next-generation Factor VIIa, in individuals with hemophilia B with inhibitors in 2017. In addition, Catalyst and its collaboration partner, ISU Abxis, plan to initiate a SQ Phase 1/2 proof-of-concept clinical trial of CB 2679d/ISU304, a next-generation coagulation Factor IX, in individuals with hemophilia B in the second quarter of 2017.
Nassim Usman, Ph.D., President and Chief Executive Officer, presented at the 19th Annual BIO CEO & Investor Conference held in New York City. A copy of Dr. Usman’s presentation slides can be found in the Investors section of the Company’s website. Read Mo
[finviz_code ticker=CBIO item=2 value=”Catalyst Biosciences, Inc.”] (NASDAQ:[finviz_code ticker=CBIO item=1 value=”CBIO”]) is all set to announce its earnings on [finviz_code ticker=CBIO item=68 value=”Feb 23/a”]. As per Zack’s analyst ratings, [finviz_code ticker=CBIO item=2 value=”Catalyst Biosciences, Inc.”] (NASDAQ:[finviz_code ticker=CBIO item=1 value=”CBIO”]) currently has an average brokerage rating of [quandl_code ticker=CBIO item=ZAR|RATING_MEAN value=”1″]. On a scale of 1 to 5, a rating of 1 or 2 would indicate a buy, and a rating of 4 or 5 would signify a sell recommendation. A rating of 3 would indicate a hold on the stock. The consensus target price on (NASDAQ:[finviz_code ticker=CBIO item=1 value=”CBIO”]) is $[quandl_code ticker=CBIO item=ZAR|TP_MEAN_EST value=”2″] with a high of $[quandl_code ticker=CBIO item=ZAR|TP_HIGH_EST value=”2″] and a low of $[quandl_code ticker=CBIO item=ZAR|TP_LOW_EST value=”2″].
Let’s take a look at the technical analysis.
[intr_chart ticker=CBIO src=”http://www.financialstrend.com/wp-content/uploads/2017/02/25584-CBIO6.png”]
[intr_bto ticker=CBIO content=”ICAgIFRoZSBCYXJjaGFydCBUZWNobmljYWwgT3BpbmlvbiByYXRpbmcgaXMgYSA0MCUgU2VsbCB3aXRoIGEgV2Vha2VuaW5nIHNob3J0IHRlcm0gb3V0bG9vayBvbiBtYWludGFpbmluZyB0aGUgY3VycmVudCBkaXJlY3Rpb24uICAgICBMb25nZXIgdGVybSwgdGhlIHRyZW5kIHN0cmVuZ3RoIGlzIFdlYWsuICAgTG9uZyB0ZXJtIGluZGljYXRvcnMgZnVsbHkgc3VwcG9ydCBhIGNvbnRpbnVhdGlvbiBvZiB0aGUgdHJlbmQuICAgICAgIA==”]
The The Exponential Moving Average (EMA) is similar to a simple moving average (average price over a set period) but it utilizes a weighting factor that exponentially declines from the most recent data point (recent prices are weighted higher than oid prices). EMA analysis compares the short term (5 days and 13 days), intermediate term (20 days) and long term (50 days) EMA’s. The respective EMA’s will give bullish signals when trading above trailing EMA’s and below the current price and vice versa. EMA alerts include crossovers (i.e the 5 day EMA crosses above/below the 20 day EMA) and EMA convergencies (5 day EMA equivalent to 13 day EMA). [ema_code ticker=CBIO color=red value=8.18|9.65].
The relative strength index (RSI) is a momentum osciallator that is able to measure the velocity and magnitude of stock price changes. Momentum is calculated as the ratio of positive price changes to negative price changes. The RSI analysis compares the current RSI against neutral(50), oversold (30) and overbought (70) conditions. Alerts will inform you when stocks recede from oversold/overbought levels or breakthrough neutral (50). [rsi_code ticker=CBIO color=red value=43.52]
